Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10754755 | 0.77 | MAP3K14 (0.48) | MAP3K14CRBNDDB1CYP19A1LMNA | |
| SCHEMBL8348991 | 0.77 | MAP3K14 (0.48) | MAP3K14CRBNDDB1CYP19A1LMNA | |
| SCHEMBL4985328 | 0.73 | — | — | |
| SCHEMBL1034864 | 0.73 | — | — | |
| SCHEMBL3998968 | 0.73 | CRBN (0.42) | MAP3K14CRBN | |
| SCHEMBL15270425 | 0.71 | — | — | |
| SCHEMBL18015890 | 0.69 | MAP3K14 (0.38) | MAP3K14CRBNDDB1CYP19A1GAA | |
| SCHEMBL3949247 | 0.68 | MAP3K14 (0.40) | MAP3K14CRBNDDB1CYP19A1LMNA | |
| SCHEMBL7264550 | 0.68 | MAP3K14 (0.40) | MAP3K14CRBNDDB1CYP19A1LMNA | |
| SCHEMBL9510783 | 0.68 | MAP3K14 (0.40) | MAP3K14CRBNDDB1CYP19A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250180990-A1 | PHOTOSENSITIVE SURFACE TREATING AGENT, LAMINATE, PATTERN FORMATION SUBSTRATE, TRANSISTOR, PATTERN FORMING METHOD AND METHOD OF PRODUCING TRANSISTOR | NIKON CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| WO-2024043222-A1 | PHOTOSENSITIVE SURFACE TREATMENT AGENT, LAMINATE, SUBSTRATE FOR PATTERN FORMATION, TRANSISTOR, PATTERN FORMATION METHOD, AND TRANSISTOR MANUFACTURING METHOD | 株式会社ニコン | 2024-02-29 | — | — | WO | disclosed |
| WO-2022138605-A1 | METHOD FOR PRODUCING PEPTIDE, REAGENT FOR FORMING PROTECTIVE GROUP, AND FUSED POLYCYCLIC COMPOUND | 富士フイルム株式会社 | 2022-06-30 | — | — | WO | disclosed |
| CN-114026110-A | Method for producing peptide compound, protecting group-forming reagent, and fused polycyclic compound | 富士胶片株式会社 | 2022-02-08 | — | — | CN | disclosed |
| EP-3489245-B1 | NEW XANTHENE PROTECTIVE AGENT | SEKISUI MEDICAL CO LTD (JP) | 2020-10-14 | — | — | EP | disclosed |
| US-20190263842-A1 | NEW XANTHENE PROTECTIVE AGENT | SEKISUI MEDICAL CO., LTD. (JP) | 2019-08-29 | — | — | US | disclosed |
| EP-3489245-A1 | NEW XANTHENE PROTECTIVE AGENT | Sekisui Medical Co., Ltd. (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-8084643-B2 | Nitrogen-containing esters of the secondary alcohol group of florfenicol and of its analogs,including salts; veterinary medicine; nonhydrolyzing as needed to maintain the prodrug in aqueous solution in the subjects system until appropriate; cattle drinking water; bovine respiratory disease | INTERVET INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8044230-B2 | Hydrolytic stability needed to maintain the prodrug in solution in the subject's system until appropriate conditions exist when the prodrug can hydrolyze, releasing the active compound | INTERVET INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2102154-A1 | WATER-SOLUBLE PRODRUGS OF CHLORAMPHENICOL, THIAMPHENICOL, AND ANALOGS THEREOF | Schering-Plough Ltd. (CH) | 2009-09-23 | — | — | EP | disclosed |
| US-6596743-B2 | Control or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
| WO-2003038092-A1 | METHOD FOR IDENTIFYING TRANSPORT PROTEINS | SYMPORE GMBH (DE) | 2003-05-08 | — | — | WO | disclosed |
| US-6462198-B1 | USED IN THE CONTROL OR PREVENTION OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS RESTRICTED BRAIN FUNCTION CAUSED BY BYPASS OPERATIONS OR TRANSPLANTS, POOR BLOOD SUPPLY TO THE BRAIN, SPINAL CORD INJURIES, HEAD INJURIES, HYPOXIA, | HOFFMANN-LA ROCHE INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020091150-A1 | Carbamic acid derivatives | BLEICHER KONRAD (DE) | 2002-07-11 | — | — | US | disclosed |
| EP-1171423-A1 | CARBAMIC ACID DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000063166-A1 | CARBAMIC ACID DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-26 | — | — | WO | disclosed |
| US-4547492-A | 1-N-(ω-Amino-α-hydroxyalkanoyl-2',3'-dideoxykanamycin A and pharmaceutical composition containing same | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-10-15 | — | — | US | disclosed |
| EP-0139553-A2 | 1N-(omega-amino-alpha-hydroxyalkanoyl)-2',3'-dideoxykanamycin A and the production of the same | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-05-02 | — | — | EP | disclosed |
| US-4248786-A | Hydroxy-succinimide ester compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1981-02-03 | — | — | US | disclosed |
| US-4155914-A | Hydroxy-succinimide ester compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250180990-A1 | PHOTOSENSITIVE SURFACE TREATING AGENT, LAMINATE, PATTERN FORMATION SUBSTRATE, TRANSISTOR, PATTERN FORMING METHOD AND METHOD OF PRODUCING TRANSISTOR | CHRM1, LMNB1, CCNT1 | MAP3K14 2673/4885CRBN 2765/4885DDB1 1054/4885 |
| US-20020091150-A1 | Carbamic acid derivatives | CHRM1, CHRNA2, CHRM2 | MAP3K14 2757/4885CRBN 3545/4885DDB1 978/4885 |
| US-20190263842-A1 | NEW XANTHENE PROTECTIVE AGENT | XDH, XPA, XPO7 | MAP3K14 1398/4885CRBN 1082/4885DDB1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.